93MO Long-term Patient-Reported Outcomes from Monarche: Abemaciclib Plus Endocrine Therapy for Adjuvant HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (EBC)
ESMO open（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined